Tamoxifen as a powerful neuroprotectant in experimental stroke and implications for human stroke therapy

Recent Patents on CNS Drug Discovery

Volumn 3, Issue 2, 2008, Pages 104-108

  Kimelberg, Harold K ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Experimental stroke; Human stroke therapy; Neuroprotectant; Tamoxifen

Indexed keywords

DISUFENTON SODIUM; ESTROGEN RECEPTOR; FULVESTRANT; GLUTAMIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; NEUROPROTECTIVE AGENT;

ARTICLE; BRAIN INFARCTION SIZE; BREAST CANCER; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; EXPERIMENTAL STUDY; HUMAN; LIPID PEROXIDATION; LOW DRUG DOSE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PATENT; PRIORITY JOURNAL; PROTEIN SECRETION; SINGLE DRUG DOSE; ANIMAL; CHEMISTRY; DISEASE MODEL; REVIEW; STROKE;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; NEUROPROTECTIVE AGENTS; STROKE; TAMOXIFEN;

EID: 49149123497     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488908784534603     Document Type: Article

References (32)

1. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999; 22: 391-397.
2. Ginsberg MD. Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: The 2002 Thomas Willis lecture. Stroke 2003; 34: 214-223.
3. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999; 79: 1431-1568.
4. Choi DW, Lobner D, Dugan LL. Glutamate receptor-mediated neuronal death in the ischemic brain. Monogr. Neural Sci 1998; 16: 2-13.
5. Cherubini A, Ruggiero C, Polidori MC, Mecocci P. Potential markers of oxidative stress in stroke. Free Radic Biol Med 2005; 39: 841-852.
6. Muir KW, Teal PA. Why have neuro-protectants failed?: Lessons learned from stroke trials. J Neurol 2005; 252: 1011-1020.
7. Kimelberg HK, Feustel PJ, Jin Y, et al. Acute treatment with tamoxifen reduces ischemic damage following middle cerebral artery occlusion. NeuroReport 2000; 11: 2675-2679.
8. Zhang Y, Jin Y, Behr MJ, Feustel PJ, Morrison JP, Kimelberg HK. Behavioral and histological neuroprotection by tamoxifen after reversible focal cerebral ischemia. Exp Neurol 2005; 196: 41-46.
9. Mehta SH, Dhandapani KM, De Sevilla LM, Webb RC, Mahesh VB, Brann DW. Tamoxifen, a selective estrogen receptor modulator, reduces ischemic damage caused by middle cerebral artery occlusion in the ovariectomized female rat. Neuroendocrinol 2003; 77: 44-50.
10. Seki Y, Feustel PJ, Keller RW Jr., Tranmer BI, Kimelberg HK. Inhibition of ischemia-induced glutamate release in rat striatum by dihydrokainate and an anion channel blocker. Stroke 1999; 30: 433-440.
11. Kimelberg HK. Astrocytic swelling in cerebral ischemia as a possible cause of injury and target for therapy. Glia 2005; 50: 389-397.
12. Feustel PJ, Jin Y, Kimelberg HK. Volume regulated anion channels are the predominant contributors to release of excitatory amino acids in the ischemic cortical penumbra. Stroke 2004; 35: 1164-1168.
13. Biegon A, Brewster M, Degani H, Pop E, Somjen D, Kaye AM. A permanently charged tamoxifen derivative idsplays anticancer activity and improved tissue selectivity in rodents. Cancer Res 1996; 56: 4328-4331.
14. Buchanan CM, Buchanan NL, Edgar KJ, et al. Pharmacokinetics of tamoxifen after intravenous and oral dosing of tamoxifenhydroxybutenyl-beta-cyclodextrin formulations. J Pharm Sci 2007; 96: 644-660.
15. Kimelberg HK, Jin Y, Feustel PJ. Neuroprotective activity of tamoxifen in permanent focal ischemia. J Neurosurgery 2003; 99: 138-142.
16. Benveniste H, Drejer J, Schousboe A, Diemer NM. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 1984; 43: 1369-1374.
17. Green AR, Ashwood T, Odergren T, Jackson DM. Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059. Pharmacol Ther 2003; 100: 195-214.
18. Osuka K, Feustel PJ, Mongin AA, Tranmer BI, Kimelberg HK. Tamoxifen inhibits nitrotyrosine formation after reversible middle cerebral artery occlusion in the rat. J Neurochem 2001; 76: 1842-1850.
19. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. Oxford University Press, Oxford, New York1999.
20. Mattson MP. Modification of ion homeostasis by lipid peroxidation: Roles in neuronal degeneration and adaptive plasticity. Trends Neurosci 1998; 21: 53-57.
21. Zhang Y, Milatovic D, Aschner M, Feustel PJ, Kimelberg HK. Neuroprotection by tamoxifen in focal cerebral ischemia is not mediated by an agonist action at estrogen receptors but is associated with antioxidant activity. Exp Neurol 2007; 204: 819-827.
22. Dhandapani KM, Brann DW. Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biol Reprod 2002; 67: 1379-1385.
23. Hurn PD, Brass LM. Estrogen and stroke: A balanced analysis. Stroke 2003; 34: 338-341.
24. Green PS, Simpkins JW. Neuroprotective effects of estrogens: Potential mechanisms of action. Int J Dev Neurosci 2000; 18: 347-358.
25. Yang SH, Shi J, Day AL, Simpkins JW. Estradiol exerts neuroprotective effects when administered after ischemic insult. Stroke 2000; 31: 745-749.
26. Wade GN, Blaustein JD, Gray JM, Meredith JM. ICI 182,780: A pure antiestrogen that affects behaviors and energy balance in rats without acting in the brain. Am J Physiol 1993; 265: R1392-R1398.
27. Couldwell WT, Weiss MH, DeGiorgio CM, et al. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurg 1993; 32: 485-489.
28. Pollack IF, DaRosso RC, Robertson PL, et al. A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin Cancer Res 1997; 3: 1109-1115
29. Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. N Engl J Med 2006; 354: 588-600.
30. Kirk J, Kirk K. Inhibition of volume-activated I and taurine efflux from HeLa cells by P-glycoprotein blockers correlates with calmodulin inhibition. J Biol Chem 1994: 269: 29389-29394.
31. Savitz SI. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: A need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol 2007; 205: 20-25.
32. Green AR, Lanbedk-Vallen K, Ashwood T, et al. Brain penetration of the novel free radical trapping neuroprotectant NXY-059 in rats subjected to permanent focal ischemia. Brain Res 2006; 1072: 224-226.